The Ethics of Continuing Placebo in SARS-CoV-2 Vaccine Trials

被引：32

作者：

Rid, Annette ^{[1
]}

Lipsitch, Marc ^{[2
]}

Miller, Franklin G. ^{[3
]}

机构：

[1] NIH, Ctr Clin, Dept Bioeth, 10 Ctr Dr,Bldg 10,Room 1C118, Bethesda, MD 20892 USA

[2] Harvard TH Chan Sch Publ Hlth, Ctr Communicable Dis Dynam, Dept Immunol & Infect Dis, Dept Epidemiol, Boston, MA USA

[3] Weill Cornell Med Coll, New York, NY USA

来源：

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2021年 / 325卷 / 03期

关键词：

D O I：

10.1001/jama.2020.25053

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This Viewpoint proposes that prioritizing all placebo-group participants in coronavirus vaccine trials as vaccine first receivers could perpetuate health inequities and compromise the chance to learn from their participation, proposing instead to limit prioritization to placebo participants who would be prioritized for vaccination anyway under NASEM or ACIP frameworks.

引用

页码：219 / 220

页数：2

共 8 条

[1] Scientific and Ethical Principles Underlying Recommendations From the Advisory Committee on Immunization Practices for COVID-19 Vaccination Implementation
Bell, Beth P.
Romero, Jose R.
Lee, Grace M.
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 324 (20): : 2025 - 2026
[2] Branswell H, 2020, STAT NEWS
[3] Grady Denise, 2020, NY TIMES
[4] Herper M., 2020, STAT NEWS
[5] Observational studies and the difficult quest for causality: lessons from vaccine effectiveness and impact studies
Lipsitch, Marc
Jha, Ayan
Simonsen, Lone
[J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2016, 45 (06) : 2060 - 2074
[6] Rid A, 2011, KENNEDY INST ETHIC J, V21, P141
[7] Sun, 2020, WASH POST
[8] COVID-19 vaccine trial ethics once we have efficacious vaccines
Wendler, David
Ochoa, Jorge
Millum, Joseph
Grady, Christine
Taylor, Holly A.
[J]. SCIENCE, 2020, 370 (6522) : 1277 - 1279

← 1 →